Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin SSD in early decompensated liver cirrhosis
NCT01904409Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jun 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rifaximin in Liver cirrhosis (LC), sponsored by Valeant Pharmaceuticals. Started Jun 2013; status: completed.
02
Drugs
rifaximin
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT01904409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01904409.